Cefepime + Zidebactam: Detailed Pharmacology
Mechanism of Action
Cefepime/zidebactam represents a novel dual-mechanism combination where zidebactam functions both as a β-lactamase inhibitor and a β-lactam enhancer (BLE), fundamentally altering cefepime's pharmacodynamic requirements for bacterial killing. 1
Cefepime Component
- Fourth-generation cephalosporin with time-dependent bactericidal activity
- Binds to penicillin-binding proteins (PBPs) to inhibit bacterial cell wall synthesis
- Exhibits activity against both Gram-positive and Gram-negative organisms
Zidebactam Component: Dual Mechanism
- β-lactamase inhibition: Inhibits Ambler class A (including ESBLs, KPC) and class C (AmpC) enzymes 2, 3
- β-lactam enhancement: High-affinity binding to PBP2, providing direct antibacterial activity 2, 3
- Does NOT inhibit: Class B metallo-β-lactamases (NDM, VIM, IMP) or most class D enzymes (OXA variants) 3
Critical pharmacodynamic alteration: Zidebactam reduces the cefepime %fT>MIC required for efficacy from traditional cephalosporin targets (60-70%) down to approximately 18% for bacteriostasis and 31% for 1-log kill against MBL-producing Enterobacterales 2. This represents a fundamental shift in how the combination achieves bacterial eradication.
Pharmacokinetics
Absorption & Distribution (at steady state with 2g cefepime/1g zidebactam q8h) 1
Cefepime:
- Cmax: 153 mg/L
- AUC₀₋₈: 362 mg·h/L
- Volume of distribution (Vz): 13.7 L
- Protein binding: 20%
Zidebactam:
- Cmax: 64.3 mg/L
- AUC₀₋₈: 153 mg·h/L
- Volume of distribution (Vz): 15.5 L
- Protein binding: 4.0-5.4%
Pulmonary Penetration 4
Epithelial Lining Fluid (ELF):
- Cefepime penetration ratio: 0.39 (39% of plasma)
- Zidebactam penetration ratio: 0.38 (38% of plasma)
- ELF AUC₀₋₈: Cefepime 127.9 mg·h/L, Zidebactam 52.0 mg·h/L
Alveolar Macrophages (AM):
- Cefepime penetration ratio: 0.27 (27% of plasma)
- Zidebactam penetration ratio: 0.10 (10% of plasma)
- AM AUC₀₋₈: Cefepime 87.9 mg·h/L, Zidebactam 13.2 mg·h/L
These concentrations support use in pneumonia caused by susceptible pathogens 4.
Metabolism & Elimination 1
Both components are minimally metabolized (<10% hepatic metabolism):
- Cefepime: 85% excreted unchanged in urine; 6.8% as N-oxide, 2.5% as epimer
- Zidebactam: 88% excreted unchanged in urine; 2.5% as impurity-1 isomer
Elimination half-lives:
- Cefepime: 1.8 hours
- Zidebactam: 1.7 hours
Clearance:
- Cefepime: 5.2 L/h
- Zidebactam: 6.2 L/h
Renal Impairment 1
Dose-normalized AUC increases compared to CrCl ≥90 mL/min:
| CrCl (mL/min) | Cefepime Fold Increase | Zidebactam Fold Increase |
|---|---|---|
| 60-89 | 1.4× | 1.3× |
| 30-59 | 3.0× | 3.3× |
| 15-29 | 4.2× | 5.4× |
| ESRD on HD | 9.9× | 16.0× |
Both drugs are hemodialyzable; administer after hemodialysis on dialysis days. 1 Dosage adjustments are mandatory for eGFR <60 mL/min to prevent accumulation and neurotoxicity 1.
Special Populations 1
No clinically significant PK differences based on:
- Age: 18-90 years
- Weight: 39-130 kg
- Gender: Male vs. female
- Race: Multiple ethnic groups studied
Hepatic impairment: No dose adjustment needed (minimal hepatic metabolism) 1
Pharmacodynamics
PK/PD Target
For both cefepime and zidebactam, %fT>MIC (percentage of time free drug concentration exceeds MIC) is the primary PK/PD driver. 1
Zidebactam's β-lactam enhancer effect dramatically reduces the cefepime exposure needed:
- Traditional cephalosporin monotherapy: 60-70% fT>MIC for efficacy
- Cefepime/zidebactam combination: 18% fT>MIC for bacteriostasis, 31% fT>MIC for 1-log kill 2
This allows lower cefepime exposures to achieve therapeutic effect while maintaining safety margins.
Cardiac Safety
At 4× the maximum recommended zidebactam dose (with standard cefepime), no clinically significant QTc prolongation observed 1.
Neurotoxicity Considerations
Cefepime-Specific Risk
Cefepime has a relative pro-convulsive activity of 160 (compared to penicillin G = 100), making it the second most neurotoxic β-lactam after cefazolin (294). 5
Neurotoxicity thresholds for cefepime:
- Trough concentrations >22 mg/L (intermittent infusion): 50% risk of neurotoxicity 5
- Steady-state concentrations >35 mg/L (continuous infusion): 50% risk of neurotoxicity 5
Risk factors:
- Renal impairment (most important—causes rapid accumulation) 5
- Inappropriately dosed for renal function (48% of neurotoxicity cases) 5
- Even appropriately dosed patients: 26% still developed neurotoxicity 5
Clinical manifestations: Encephalopathy, confusion, hallucinations, stupor, coma, myoclonus, seizures, neuromuscular excitability, nonconvulsive status epilepticus 1
Monitoring & Management
Monitor renal function regularly during therapy and adjust doses accordingly as renal function may change. 1 For unexplained neurological symptoms in patients receiving cefepime/zidebactam:
- Consider therapeutic drug monitoring (TDM)
- Temporarily suspend administration
- Both drugs are hemodialyzable if overdose occurs 1
Target plasma concentrations: Avoid exceeding 8× MIC for the fCmin/MIC ratio to maintain favorable benefit-risk balance 5. Beyond this threshold, neurological deterioration risk increases substantially without additional efficacy benefit.
Clinical Implications
Dosing Strategy
- Standard dose: 2g cefepime/1g zidebactam IV q8h 1
- Infusion time: Typically 1 hour (extended infusions may be considered for critically ill patients based on general β-lactam principles 5)
- Mandatory dose adjustment for CrCl <60 mL/min 1
Spectrum Considerations 3, 6
- Active against: ESBL-, AmpC-, KPC-producing Enterobacterales; difficult-to-treat P. aeruginosa; OXA-48-producing strains
- NOT active against: MBL-producing organisms (NDM, VIM, IMP); most OXA-23-producing Acinetobacter (though some activity reported 7)
Resistance Mechanisms to Monitor 3, 6
- PBP alterations (especially PBP2 mutations)
- Porin loss (OmpK35/36 in Klebsiella)
- Efflux pump overexpression
- Evolving KPC variants
- Combination of multiple mechanisms